Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02729103 · ClinicalTrials.gov registry record
Treatment Patterns in Metastatic Prostate Cancer
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 565
- Enrollment target
NCT02729103 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 565 participants.
The verdict
NCT02729103 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 565 participants
- Enrollment target
Study Summary
This study will evaluate treatment patterns, mortality, healthcare resource utilization, and costs in patients with prostate cancer with bone metastases (primary objectives). Additionally, this study will evaluate opioid/analgesic use among lines of therapy in this patient population (secondary objective). The study is descriptive in nature and is meant to provide a greater understanding of the patterns of therapy observed in real-world clinical practice (in the absence of clear guideline recommendations with regards to treatment sequencing), to contribute to a greater understanding of the major cost drivers (thus better-informing payers), and to examine real-world mortality in such patients.
Interventions
- DRUG Xofigo (Radium 223 dichloride,BAY88-8223)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 565 participants |
| Start Date | 2016-10-31 |
| Est. Completion | 2017-01-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02729103
The ClinicalTrials.gov registry entry for NCT02729103 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 565 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xofigo (Radium 223 dichloride,BAY88-8223) is the first listed.
NCT02729103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02729103 about?
NCT02729103 is a clinical study titled "Treatment Patterns in Metastatic Prostate Cancer". This study will evaluate treatment patterns, mortality, healthcare resource utilization, and costs in patients with prostate cancer with bone metastases (primary objectives). Additionally, this study will evaluate opioid/analgesic use among lines of therapy in this patient population (secondary obje...
What is the current status of trial NCT02729103?
This trial is currently completed. The enrollment target is 565 participants. The study started on 2016-10-31. Estimated completion is 2017-01-19.
What interventions are being tested in trial NCT02729103?
The interventions under investigation include: Xofigo (Radium 223 dichloride,BAY88-8223) (DRUG).
Who is sponsoring clinical trial NCT02729103?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.